Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation

NCT07211958 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

468

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemias

Interventions

DRUG: Revumenib
DRUG: Placebo
DRUG: Intensive Chemotherapy Regimen

Sponsor

Syndax Pharmaceuticals